Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages - PubMed (original) (raw)
. 2012 Feb 1;188(3):1117-24.
doi: 10.4049/jimmunol.1100164. Epub 2011 Dec 19.
Affiliations
- PMID: 22184722
- DOI: 10.4049/jimmunol.1100164
Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages
Qiyi Zhao et al. J Immunol. 2012.
Abstract
Substantial evidence indicates that immune activation at stroma can be rerouted in a tumor-promoting direction. CD69 is an immunoregulatory molecule expressed by early-activated leukocytes at sites of chronic inflammation, and CD69(+) T cells have been found to promote human tumor progression. In this study, we showed that, upon encountering autologous CD69(+) T cells, tumor macrophages (MΦs) acquired the ability to produce much greater amounts of IDO protein in cancer nests. The T cells isolated from the hepatocellular carcinoma tissues expressed significantly more CD69 molecules than did those on paired circulating and nontumor-infiltrating T cells; these tumor-derived CD69(+) T cells could induce considerable IDO in monocytes. Interestingly, the tumor-associated monocytes/MΦs isolated from hepatocellular carcinoma tissues or generated by in vitro culture effectively activated circulating T cells to express CD69. IL-12 derived from tumor MΦs was required for early T cell activation and subsequent IDO expression. Moreover, we found that conditioned medium from IDO(+) MΦs effectively suppressed T cell responses in vitro, an effect that could be reversed by adding extrinsic IDO substrate tryptophan or by pretreating MΦs with an IDO inhibitor 1-methyl-DL-tryptophan. These data revealed a fine-tuned collaborative action between different types of immune cells to counteract T cell responses in tumor microenvironment. Such an active induction of immune tolerance should be considered for the rational design of effective immune-based anticancer therapies.
Similar articles
- Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients.
Zhao Q, Xiao X, Wu Y, Wei Y, Zhu LY, Zhou J, Kuang DM. Zhao Q, et al. Eur J Immunol. 2011 Aug;41(8):2314-22. doi: 10.1002/eji.201041282. Epub 2011 Jul 4. Eur J Immunol. 2011. PMID: 21674477 - Multiple myeloma cell-derived IL-32γ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression.
Yan H, Dong M, Liu X, Shen Q, He D, Huang X, Zhang E, Lin X, Chen Q, Guo X, Chen J, Zheng G, Wang G, He J, Yi Q, Cai Z. Yan H, et al. Cancer Lett. 2019 Apr 1;446:38-48. doi: 10.1016/j.canlet.2019.01.012. Epub 2019 Jan 18. Cancer Lett. 2019. PMID: 30660652 - Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation.
Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Hwu P, et al. J Immunol. 2000 Apr 1;164(7):3596-9. doi: 10.4049/jimmunol.164.7.3596. J Immunol. 2000. PMID: 10725715 - Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M, Germenis AE, Karanikas V. Zamanakou M, et al. Immunol Lett. 2007 Aug 15;111(2):69-75. doi: 10.1016/j.imlet.2007.06.001. Epub 2007 Jul 2. Immunol Lett. 2007. PMID: 17644189 Review. - The immunoregulatory function of indoleamine 2, 3 dioxygenase and its application in allotransplantation.
Jalili RB, Forouzandeh F, Bahar MA, Ghahary A. Jalili RB, et al. Iran J Allergy Asthma Immunol. 2007 Dec;6(4):167-79. Iran J Allergy Asthma Immunol. 2007. PMID: 18094439 Review.
Cited by
- Targeting amino acid-metabolizing enzymes for cancer immunotherapy.
Grobben Y. Grobben Y. Front Immunol. 2024 Aug 14;15:1440269. doi: 10.3389/fimmu.2024.1440269. eCollection 2024. Front Immunol. 2024. PMID: 39211039 Free PMC article. Review. - Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy.
Nicolini A, Ferrari P. Nicolini A, et al. Front Immunol. 2024 Jul 25;15:1353787. doi: 10.3389/fimmu.2024.1353787. eCollection 2024. Front Immunol. 2024. PMID: 39119332 Free PMC article. Review. - Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside.
Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S, Xu X, Nie Y, Fan D, Wu K, Xia L. Yin Y, et al. Exp Hematol Oncol. 2024 Aug 1;13(1):72. doi: 10.1186/s40164-024-00539-x. Exp Hematol Oncol. 2024. PMID: 39085965 Free PMC article. Review. - Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress.
Li Z, Duan D, Li L, Peng D, Ming Y, Ni R, Liu Y. Li Z, et al. Front Pharmacol. 2024 Jun 18;15:1382256. doi: 10.3389/fphar.2024.1382256. eCollection 2024. Front Pharmacol. 2024. PMID: 38957393 Free PMC article. Review. - Identification of immune cell-related prognostic genes characterized by a distinct microenvironment in hepatocellular carcinoma.
Li MT, Zheng KF, Qiu YE. Li MT, et al. World J Clin Oncol. 2024 Feb 24;15(2):243-270. doi: 10.5306/wjco.v15.i2.243. World J Clin Oncol. 2024. PMID: 38455128 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials